308 related articles for article (PubMed ID: 24563531)
1. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
[TBL] [Abstract][Full Text] [Related]
2. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.
Canal CE; Booth RG; Morgan D
Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901
[TBL] [Abstract][Full Text] [Related]
3. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
4. (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.
Booth RG; Fang L; Huang Y; Wilczynski A; Sivendran S
Eur J Pharmacol; 2009 Aug; 615(1-3):1-9. PubMed ID: 19397907
[TBL] [Abstract][Full Text] [Related]
5. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.
Canal CE; Cordova-Sintjago T; Liu Y; Kim MS; Morgan D; Booth RG
J Pharmacol Exp Ther; 2013 Dec; 347(3):705-16. PubMed ID: 24080681
[TBL] [Abstract][Full Text] [Related]
6. A new class of 5-HT
Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
[TBL] [Abstract][Full Text] [Related]
7. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
8. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.
Morgan D; Kondabolu K; Kuipers A; Sakhuja R; Robertson KL; Rowland NE; Booth RG
Neuropharmacology; 2013 Sep; 72():274-81. PubMed ID: 23665356
[TBL] [Abstract][Full Text] [Related]
9. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.
Fantegrossi WE; Simoneau J; Cohen MS; Zimmerman SM; Henson CM; Rice KC; Woods JH
J Pharmacol Exp Ther; 2010 Dec; 335(3):728-34. PubMed ID: 20858706
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.
Zhang G; Cheng J; McCorvy JD; Lorello PJ; Caldarone BJ; Roth BL; Kozikowski AP
J Med Chem; 2017 Jul; 60(14):6273-6288. PubMed ID: 28657744
[TBL] [Abstract][Full Text] [Related]
11. Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors.
Su YA; Si TM; Zhou DF; Guo CM; Wang XD; Yang Y; Shu L; Liang JH
Eur J Pharmacol; 2007 Jun; 564(1-3):123-30. PubMed ID: 17395179
[TBL] [Abstract][Full Text] [Related]
12. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
Kim SK; Li Y; Abrol R; Heo J; Goddard WA
J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
[TBL] [Abstract][Full Text] [Related]
14. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
McFarland K; Price DL; Bonhaus DW
Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
[TBL] [Abstract][Full Text] [Related]
15. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
16. Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT
Carpenter J; Wang Y; Wu G; Feng J; Ye XY; Morales CL; Broekema M; Rossi KA; Miller KJ; Murphy BJ; Wu G; Malmstrom SE; Azzara AV; Sher PM; Fevig JM; Alt A; Bertekap RL; Cullen MJ; Harper TM; Foster K; Luk E; Xiang Q; Grubb MF; Robl JA; Wacker DA
J Med Chem; 2017 Jul; 60(14):6166-6190. PubMed ID: 28635286
[TBL] [Abstract][Full Text] [Related]
17. Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
Cheng J; Giguère PM; Onajole OK; Lv W; Gaisin A; Gunosewoyo H; Schmerberg CM; Pogorelov VM; Rodriguiz RM; Vistoli G; Wetsel WC; Roth BL; Kozikowski AP
J Med Chem; 2015 Feb; 58(4):1992-2002. PubMed ID: 25633969
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
[TBL] [Abstract][Full Text] [Related]
19. 5-HT
Faton S; Tassin JP; Duranton F; Bagnol D; Lajoix AD
Behav Brain Res; 2018 Jul; 347():234-241. PubMed ID: 29555337
[TBL] [Abstract][Full Text] [Related]
20. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.
Reid TE; Kumar K; Wang XS
Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
